Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SALIF: Switching to TDF/FTC/RPV vs TDF/FTC/EFV in Suppressed HIV-1 Patients
NCT01709084Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2013
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of rilpivirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Janssen Pharmaceutical. Started Oct 2013; status: completed.
02
Drugs
rilpivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01709084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01709084.